50 W Broadway, 3rd Floor • Salt Lake City, UT 84101
|
SAB Capra LLC

News

Our Story

SAB Capra, LLC. is a privately-held, emerging bioscience company developing targeted human polyclonal antibodies for use in diagnostics and testing, immunotherapeutics and personalized medicine applications. The company is advancing its novel antibody production platform leveraging transgenic goats utilizing some of the most advanced polyclonal science in the world.

The company is a Utah-based wholly owned subsidiary of SAB Biotherapeutics, Inc. a clinical-stage biopharmaceutical company developing human antibody therapeutics using its first-of-its-kind natural human immunotherapy platform leveraging transgenic animals genetically designed to produce large amounts of human polyclonal antibodies in response to a target disease.  

Our Beginning

Headquartered in Salt Lake City, Utah SAB Capra was organized through a collaboration with Utah State University researchers, Dr. Irina Polejaeva and Dr. Zhongde Wang. The initial research project was supported by a grant from Utah Science Technology and Research initiative (USTAR), a technology based economic development initiative funded by the state of Utah. Read more.

USTAR is a technology based economic development initiative funded by the state of Utah.

Subscribe

Sign up to hear from us.

Collaborators